Clinical evaluation of cefazedone.
The results of clinical trials with (6R,7R)-7-(2-[3,5-dichloro-4-oxo-1(4H)-pyridyl]-acetamido)-3-([(5-methyl-1,3,4-thiadiazol-2-yl)-thio]methyl)-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid (cefazedone, Refosporen), a new cephalosporin derivative, are reported. Overall clinical assessment in a variety of indications, including urinary tract infections, respiratory tract infections, biliary tract and other abdominal infections, surgical and dermatological infections, gynaecological infections, on 699 patients showed very good and good results in 90.5% of patients. No difference in clinical effect was seen between twice daily and three times daily dosage. Local and general tolerance was very good. Changes in laboratory parameters attributable to the drug were infrequent and returned mostly from pathological to normal.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001660:Biliary Tract Diseases / Q000188:drug therapy; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins